GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.

Science progress

Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.

Annals of internal medicine

Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.

Advances in therapy

Outcomes of Body Contouring Surgery After Bariatric Surgery vs. GLP-1 Receptor Agonist-Induced Weight Loss: A Propensity Score Matched Analysis.

Aesthetic plastic surgery

Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

Disease-a-month : DM

Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.

ESC heart failure

Hemodynamic Changes in Response to GLP-1 Treatment in ICD and CRT Patients: Insights From HeartLogic Sensor Data.

European journal of heart failure

Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.

Frontiers in endocrinology

@TheLongInvest For now, it's $HIMS. But I suspect it'll be $AVCT #AVCT in the not-too-distant future. The large majority of US retail associate #peptides with the GLP-1 mimetics (semaglutide, tirzepatide) and bioregulatory / research peptides (e.g. BPC-157; TB-500; GHK-Cu, etc.). But the

🚨 $HIMS +46% in 1 week as FDA schedules peptide compounding review (July 23–24) The FDA will evaluate 7 peptides for compounding eligibility: → BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon ✅Hims & Hers CMO called it an “avenue toward trusted channels” This is https://t.co/yKIFM6lEZh

New blog live on PeptiDex discussing the new FDA Peptide Reclassifications for 2026! It discusses the 14 peptides (BPC-157, Ipamorelin, CJC-1295, GHK-cu, MOTS-c, Selank, Semax, +++) which will be re-legalized & what exactly it entails! vvv https://t.co/k3P9TalgOf https://t.co/30qiSVu9qv

BREAKING NEWS: Peptides are coming In July, the FDA is reviewing BPC-157, TB-500, Semax, Epitalon and more. The meeting will be open to the public. The peptide era begins. https://t.co/hGR3ZPfhnU

On July 23–24, 2026, an FDA advisory committee will evaluate whether multiple peptide substances—BPC-157, KPV, TB-500, MOTS-C, emideltide (DSIP), semax, and epitalon—should be added to the 503A compounding list, including review of proposed uses and sponsor presentations.

🚨 $KITL BULLISH ALERT: FDA Peptide Reversal = Massive Catalyst for the OTC Pioneer! With RFK Jr. at HHS and the FDA now actively weighing the lift on restrictions for ~14 key peptides (BPC-157, TB-500, CJC-1295, GHK-Cu, and more), the gray-market peptide era is ending — and

• HHS Secretary Kennedy just announced the FDA is removing 12 key peptides from Category 2 restrictions starting with BPC-157 and others moving to full scientific review. • $HIMS is not a GLP-1 only company. The entire peptide industry stands ready to boom as regulated access https://t.co/3HzcTJWfS0 https://t.co/9UySm2FWBU

@LeRoi__Bear @TheDrMAWZ @sarasteinmd BPC-157: Synthetic stomach peptide promoting angiogenesis and repair. Strong animal data for tendon/wound/gut healing, NSAID alternative; limited human trials, unapproved. Rare sides, mostly none reported. GLP-1 agonists (semaglutide etc.): Curb cravings/appetite. Emerging